Letter to the editor: Hypoplastic anemia in a hemophiliac first infused with a solvent/detergent treated factor VIII concentrate: The role of human B19 parvovirus

Morfini, M.; Longo, G.; Ferrini, Pierluigi Rossi; Azzi, Alberta; Zakrewska, C.; Ciappi, S.; Kolumban, P.

doi:10.1002/ajh.2830390217

Cited by 63 publications

(32 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Recent studies have shown that B19 DNA sequences are present in a range of blood products [5,6]. Although B19 is normally spread via the respiratory route, parenteral transmission can occur through the administration of blood products made from plasma pools contaminated with B19 [7][8][9]. Despite the presence of antibodies to B19 in all plasma pools, some products made from contaminated pools have been recently reported [9] to transmit B19 as a result of the high viral load.…”

Section: Introductionmentioning

confidence: 99%

Establishment of the first World Health Organization International Standard for human parvovirus B19 DNA nucleic acid amplification techniques

Saldanha

Lelie²,

et al. 2002

Vox Sanguinis

View full text Add to dashboard Cite

Background and Objectives A collaborative study, involving 26 laboratories from 14 countries, was carried out in order to establish a World Health Organization (WHO) International Standard for human parvovirus B19 (B19) DNA nucleic acid amplification techniques (NAT). Materials and methodsFour samples: AA, BB (which were lyophilized), CC and DD (which were liquid preparations) were analysed using several different NAT assays. The mean B19 DNA content of each sample was determined for each laboratory using an end-point dilution method.Results There was good agreement between the overall mean 'equivalents'/ml obtained by the different assays. The mean log 10 'equivalents'/ml were 5·76 for sample AA, 5·73 for sample BB, 5·82 for sample CC and 7·70 for sample DD. The differences in titre among samples AA, BB and CC were not statistically significant, but the titre of DD was significantly higher.

show abstract

Section: Introductionmentioning

confidence: 99%

Establishment of the first World Health Organization International Standard for human parvovirus B19 DNA nucleic acid amplification techniques

Saldanha

Lelie²,

et al. 2002

Vox Sanguinis

View full text Add to dashboard Cite

show abstract

“…However, parenteral transmission of B19 has been documented through transfusion of individual units of infected blood or blood products [2, 3, 4]. In fact, B19 was first discovered while screening blood donors for hepatitis B virus [5].…”

Section: Introductionmentioning

confidence: 99%

“…Blood donor units are not screened currently for B19, as it has been felt that single donor blood products seldom transmit B19, and may in fact, transmit protective antibodies passively when present. In contrast, clotting factor concentrates, made from large pools of donor blood, have a much greater potential to be infectious, since neither solvent-detergent nor heat treatments used in processing are effective against this nonenveloped virus [2, 4]. …”

Section: Introductionmentioning

confidence: 99%

Human Parvovirus B19:& ;Prevalence of Viral DNA in Volunteer Blood Donors and Clinical Outcomes of Transfusion Recipients

Jordan¹,

Tiangco²,

Kiss³

et al. 1998

Vox Sanguinis

View full text Add to dashboard Cite

Background and Objectives: Blood donor units are not screened for human parvovirus B19 (B19) even though it can be acquired via blood products. We estimated the prevalence of B19 in a US volunteer blood donor population and determined the clinical outcomes of transfusion recipients. Materials and Methods: Donor units were screened for B19 DNA by PCR, and positive units analyzed by EIA for B19 Ig. Unit usage was determined and recipient chart review conducted. Results: B19 DNA was detected in 11/9, 568 allogeneic units (0.1%), of which 3 had no measurable B19 Ig. One individual developed anemia consistent with B19 infection after receiving a DNA+ unit lacking B19 Ig. Conclusions: The apparent low incidence of disease in patients transfused with B19 DNA+ components may be due to coexistence of neutralizing antibodies in donors and/or recipients.

show abstract

“…4 Transient hypoplastic anemia has been described in patients with hemophilia, and was related to human parvovirus-B19 infection transmitted by clotting factor concentrates. 2,3 Our patient developed severe aplastic anemia, but no evidence of a viral etiology was found despite extensive investigations.…”

mentioning

confidence: 99%

“…Hypoplastic anemia has been described in patients with hemophilia, and is usually associated with human parvovirus-B19 infection. 2,3 We describe the case of a young boy with congenital hemophilia A and acquired severe aplastic anemia (SAA), who was successfully treated by allogeneic bone marrow transplantation (allo-BMT) with his unaffected brother as donor.…”

mentioning

confidence: 99%

Allogeneic bone marrow transplantation in a child with severe aplastic anemia and hemophilia A

Ostronoff

Campos

et al. 2006

Bone Marrow Transplant

View full text Add to dashboard Cite

Letter to the editor: Hypoplastic anemia in a hemophiliac first infused with a solvent/detergent treated factor VIII concentrate: The role of human B19 parvovirus

Cited by 63 publications

References 8 publications

Establishment of the first World Health Organization International Standard for human parvovirus B19 DNA nucleic acid amplification techniques

Establishment of the first World Health Organization International Standard for human parvovirus B19 DNA nucleic acid amplification techniques

Human Parvovirus B19:& ;Prevalence of Viral DNA in Volunteer Blood Donors and Clinical Outcomes of Transfusion Recipients

Allogeneic bone marrow transplantation in a child with severe aplastic anemia and hemophilia A

Contact Info

Product

Resources

About